Trial
NCT06619522
A Phase 2 Study of INCB57643 (BET Inhibitor) in Combination With Ruxolitinib in JAK Inhibitor-naïve Patients With Myelofibrosis
Phase IIWITHDRAWNOPERATIONALConfidence: HIGH
Sponsor
M.D. Anderson Cancer Center
Collaborators
—
Condition
Myelofibrosis
Intervention
Ruxolitinib
Why stopped
0 participant accrual
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-05-22